Cocrystal Pharma, Inc. develops antiviral therapeutics using a proprietary structure-based drug discovery platform. News for COCP centers on CDI-988, an oral direct-acting protease inhibitor for norovirus infection, including clinical-study updates, FDA Fast Track designation and scientific presentations on its 3CL protease mechanism.
Company updates also cover financial results, financing activity, NIH-supported influenza A/B polymerase research, and broader pipeline references to respiratory viruses and coronaviruses.
Cocrystal Pharma (Nasdaq: COCP) reported Q2 2024 financial results and provided updates on its antiviral drug development programs. Key highlights include:
1. Expects topline results in 2025 from Phase 2a influenza A study with oral CC-42344
2. In vitro testing shows CC-42344 inhibits avian influenza A (H5N1) PB2 protein
3. Anticipates topline results in late 2024/early 2025 from Phase 1 study with oral CDI-988
4. Plans to initiate Phase 1 study in 2025 with inhaled CC-42344
Financial results: Q2 2024 net loss of $5.3 million ($0.54 per share) compared to Q2 2023 net loss of $4.2 million ($0.41 per share). R&D expenses increased to $4.3 million from $2.8 million in Q2 2023. Cash position of $18.1 million as of June 30, 2024.
Cocrystal Pharma (Nasdaq: COCP) reported favorable safety and tolerability results from the single-ascending dose (SAD) cohorts of its Phase 1 study for CDI-988, an oral pan-viral norovirus/coronavirus protease inhibitor. The study, conducted in Australia, evaluated doses ranging from 100 mg to 600 mg in healthy adults. Key findings include:
- No serious adverse events or severe treatment-emergent adverse events
- No clinically significant observations in laboratory assessments, physical exams, or electrocardiograms
- All participants completed the study with no discontinuations
CDI-988 is being developed as the first dual, broad-spectrum antiviral for norovirus and coronavirus treatment. The company plans to begin multiple-ascending dose (MAD) cohorts in Q4 2024.
Cocrystal Pharma (Nasdaq: COCP) has announced that its novel antiviral, CC-42344, shows promise against the highly pathogenic avian influenza A (H5N1) strain. Recent in vitro studies indicate that CC-42344 inhibits the influenza A virus's PB2 protein, essential for replication and transcription. The drug is currently in a Phase 2a clinical trial assessing its safety, tolerability, and antiviral benefits in influenza A patients, with top-line results expected in late 2024. Previously, a Phase 1 study in healthy volunteers demonstrated favorable safety and tolerability. The company used its proprietary structure-based platform to create a high-resolution crystal structure of the avian PB2 protein, confirming CC-42344's binding efficacy. The CDC has reported recent avian flu outbreaks in the U.S., including infections in dairy cows affecting humans.
Cocrystal Pharma, Inc. (Nasdaq: COCP) reports first-quarter 2024 financial results and updates on its antiviral drug-development programs. Topline results expected for Phase 1 oral CDI-988 and Phase 2a influenza A study. FDA feedback on CC-42344, initiation of Phase 1 study for inhaled CC-42344 planned. Positive cash flow management, $21.8 million cash on hand.
Cocrystal Pharma, Inc. completes enrollment of a Phase 2a study for its oral antiviral candidate CC-42344, aiming to combat pandemic and seasonal influenza. The study evaluated safety, tolerability, and antiviral effects of the drug. The company received positive Pre-IND feedback from the FDA for a proposed Phase 2b study. Cocrystal plans to start a Phase 1 study in Australia for an inhaled formulation of CC-42344. Recent preclinical data indicates promising results for the drug.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.